Open-label, phase 3 trial Unresectable hepatocellular carcinoma and no previous systemic treatment Tremelimumab (300 mg, one dose) plus durvalumab (1500 mg every 4 weeks; STRIDE,

20 Aug

Non-Small Cell Lung Cancer

New Indication: Pembrolizumab for Early-Stage NSCLC

A Phase III placebo-controlled, Randomized, Open-label trial (KEYNOTE-671) Resectable, early stage (stage II and III) NSCLC Arm A: Pembrolizumab + chemotherapyS->Pembrolizumab (

20 Aug

GastroEsophageal Cancer

New Reference: Trastuzumab Deruxtecan in her2-Positive Advanced Gastroesophageal Cancer

Single-arm, multicenter, phase II trial HER2 positive, unresectable or metastatic gastric or gastro-oesophageal junction cancer, progressive disease on or after first-line therapy

24 Jun

Breast Cancer

New Indication: Adjuvant Ribociclib and Endocrine Therapy in Breast Cancer

A Phase III Multi-center, Randomized, Open-label trial (NATALEE) Hormone Receptor-positive, HER2-negative Early Breast Cancer (Stage IIa-III) Ribociclib (400 mg/day) + ET (n=2549)

24 Jun

Prostate Cancer

New Indication: Talazoparib and Enzalutamide in Metastatic CRPC

Double-blind, placebo-controlled phase 3 trial (TALAPRO-2) Previously untreated, CRPC Enzalutamide + talazoparib (n=402) vs. Enzalutamide+ PBO (n=403

24 Jun

Renal Cell Carcinoma

New Protocol: Belzutifan and Cabozantinib for Advanced RCC

Phase II, single-arm, open-label, multicenter study Locally advanced or metastatic clear cell renal cell carcinoma had previously received immunotherapy and up to two systemic tre

24 Jun

Biliary Tract Cancer

New Protocol: Tucatinib and Trastuzumab in her2-Positive Biliary Tract Cancer

Phase II, basket study (SGNTUC-019) Previously treated with and progressed after ≥1 line of systemic therapy for HER2-positive metastatic disease. Tucatinib (TUC) + Trastuzumab

24 Jun

Non-Small Cell Lung Cancer

New Reference: Encorafenib and Binimetinib in bRAF V600E Mutated NSCLC

Phase II, single-arm study (PHAROS) Treatment-naïve and previously treated with BRAFV600E-mutant metastatic NSCLC Encorafenib +Bininmetinib q28 (n=98)

24 Jun

GastroEsophageal Cancer

New Protocol: Trastuzumab, Ramucirumab, and PACLitaxel for her2-Positive Advanced Gastroesophageal Cancer

Open-label, multicenter, phase Ib/II trial HER2-positive advanced G/GEJ cancer that progressed from trastuzumab-containing first-line chemotherapy with fluoropyrimidine and platin

Easiest Access to Our Chemotherapy Protocol Library

Download our mobile app on iOS or Android to easily access our cancer protocol library, calculate chemotherapy doses, staging library, and access to the reference summaries